Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") | ||
| By: Nasdaq / GlobeNewswire - 29 Jul 2015 | Back to overview list |
|
REGULATED INFORMATION GHENT, Belgium, 29 July 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Taube Hodson Stonex Partners LLP. Taube Hodson Stonex Partners LLP notified Ablynx that they have dropped below the 5% threshold and now hold 2,410,681 Ablynx shares, which represent 4.42% of the current 54,487,457 outstanding Ablynx shares. Full versions of all transparency notifications are available on Ablynx website, under the section Investors . About Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies® , proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Merck Serono, Novartis and Taisho Pharmaceutical. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com . Voor bijkomende informatie, gelieve contact op te nemen met Ablynx:
Dr Edwin Moses
Marieke Vermeersch
Ablynx media relaties Instinctif Partners:
Sue Charles, Daniel Gooch
Jim Rusagara
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via GlobeNewswire
HUG#1941813
|
||
|
||
 | Back to overview list | |